Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To be available in packs of 30 MIU, and 48 MIU
Subscribe to our email newsletter
Teva UK has entered the G-CSF therapy area, by developing biosimilar medicines. The company has launched its proprietary version of filgrastim,’TevaGrastim’.
TevaGrastim is licensed for a number of indications, the most common being the reduction of chemotherapy-induced neutropenia. The product is available in two presentations, both are available from wholesalers in packs of 30 MIU pre-filled syringe (5 pack), and 48 MIU pre-filled syringe (5 pack).
TevaGrastim is licensed for the same indications as the reference product, Neupogen (filgrastim). Teva’s pre-filled syringe will also incorporate a needle guard to minimise the risk of needle stick injuries.
When comparing NHS list prices of filgrastim products, TevaGrastim is a competitively priced G-CSF treatment.